galactomannan has been researched along with Sepsis* in 3 studies
2 review(s) available for galactomannan and Sepsis
Article | Year |
---|---|
Blood-based Diagnosis of Invasive Fungal Infections in Immunocompromised/Oncology Patients.
Topics: beta-Glucans; Biomarkers; DNA, Fungal; Fungemia; Galactose; Humans; Immunocompromised Host; Mannans; Neoplasms; Sepsis | 2015 |
[Methods for laboratory identification of sepsis pathogens].
Topics: Antigens, Fungal; Aspergillus; Calcitonin; Candida; Galactose; Gram-Negative Bacteria; Humans; Lipopolysaccharides; Mannans; Microbiological Techniques; Molecular Diagnostic Techniques; Mycoses; Protein Precursors; Sepsis | 2010 |
1 other study(ies) available for galactomannan and Sepsis
Article | Year |
---|---|
Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease.
Diagnosis of invasive fungal disease (IFD) in patients under intensive care is challenging. Circulating biomarkers, (1,3)-β-D-glucan (BG) and galactomannan (GM), were prospectively assessed in 98 critically ill patients at risk of IFD. There were 11 cases of invasive aspergillosis (IA; 4 proven and 7 probable), 9 cases of proven invasive candidiasis (IC), 1 case of mixed proven IC and probable IA, 1 case of proven zygomycosis, and 1 case of mixed mycelial proven IFD. In all IA cases there was no significant difference when the area under the receiver operating characteristic curve (AUC) of GM (0.873 [95%CI, 0.75-0.99]) and BG (0.856 [95% CI, 0.71-0.99]) were compared (p = 0.871). The AUC for BG in IC and for the rest of the IFD cases was 0.605 (95% CI, 0.39-0.82) and 0.768 (95% CI, 0.63-0.90) respectively. Positive BG (40%) predated blood culture (n = 3) and abdominal pus (n = 1) a mean of 3.25 days before Candida was grown. In patients with IFD caused by molds, BG appeared a mean of 5.65 days before culture results. For the diagnosis of patients at risk of IC, BG has shown a high NPV (94.5%), with positive results also predating blood cultures in 30% of patients. In conclusion, early BG results permit a timely initiation of antifungal therapy in patients at risk of IFD. Topics: Adult; Aged; Aged, 80 and over; beta-Glucans; Critical Illness; Female; Galactose; Humans; Male; Mannans; Middle Aged; Mycoses; Prospective Studies; Proteoglycans; ROC Curve; Sepsis | 2012 |